These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 27934879)

  • 1. Xp11.2 translocation renal cell carcinoma with NONO-TFE3 gene fusion: morphology, prognosis, and potential pitfall in detecting TFE3 gene rearrangement.
    Xia QY; Wang Z; Chen N; Gan HL; Teng XD; Shi SS; Wang X; Wei X; Ye SB; Li R; Ma HH; Lu ZF; Zhou XJ; Rao Q
    Mod Pathol; 2017 Mar; 30(3):416-426. PubMed ID: 27934879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinicopatholigic features of renal cell carcinoma associated with chromosome X inversion harboring gene fusions involving TFE3].
    Zhao YN; Wang XT; Xia QY; Wang GP; Sun SY; Zhao LF; Zhou XJ; Rao Q
    Zhonghua Bing Li Xue Za Zhi; 2018 Aug; 47(8):574-579. PubMed ID: 30107660
    [No Abstract]   [Full Text] [Related]  

  • 3. Xp11 Translocation Renal Cell Carcinomas (RCCs) With RBM10-TFE3 Gene Fusion Demonstrating Melanotic Features and Overlapping Morphology With t(6;11) RCC: Interest and Diagnostic Pitfall in Detecting a Paracentric Inversion of TFE3.
    Xia QY; Wang XT; Zhan XM; Tan X; Chen H; Liu Y; Shi SS; Wang X; Wei X; Ye SB; Li R; Ma HH; Lu ZF; Zhou XJ; Rao Q
    Am J Surg Pathol; 2017 May; 41(5):663-676. PubMed ID: 28288037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The suitability of NONO-TFE3 dual-fusion FISH assay as a diagnostic tool for NONO-TFE3 renal cell carcinoma.
    Liu N; Guo W; Shi Q; Zhuang W; Pu X; Chen S; Qu F; Xu L; Zhao X; Li X; Zhang G; Guo H; Gan W; Li D
    Sci Rep; 2020 Oct; 10(1):16361. PubMed ID: 33004995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Xp11.2 translocation renal neoplasm with features of TFE3 rearrangement associated renal cell carcinoma and Xp11 translocation renal mesenchymal tumor with melanocytic differentiation harboring NONO-TFE3 fusion gene.
    Yu W; Wang Y; Rao Q; Jiang Y; Zhang W; Li Y
    Pathol Res Pract; 2019 Sep; 215(9):152521. PubMed ID: 31277953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PSF/SFPQ is a very common gene fusion partner in TFE3 rearrangement-associated perivascular epithelioid cell tumors (PEComas) and melanotic Xp11 translocation renal cancers: clinicopathologic, immunohistochemical, and molecular characteristics suggesting classification as a distinct entity.
    Rao Q; Shen Q; Xia QY; Wang ZY; Liu B; Shi SS; Shi QL; Yin HL; Wu B; Ye SB; Li L; Chen JY; Pan MH; Li Q; Li R; Wang X; Zhang RS; Yu B; Ma HH; Lu ZF; Zhou XJ
    Am J Surg Pathol; 2015 Sep; 39(9):1181-96. PubMed ID: 26274027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.
    Argani P; Zhong M; Reuter VE; Fallon JT; Epstein JI; Netto GJ; Antonescu CR
    Am J Surg Pathol; 2016 Jun; 40(6):723-37. PubMed ID: 26975036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Rare Partner of TFE3 in the Xp11 Translocation Renal Cell Carcinoma: Clinicopathological Analyses and Detection of MED15-TFE3 Fusion.
    Ye H; Qin S; Li N; Lin M; Xu Y; Li X
    Biomed Res Int; 2019; 2019():5974089. PubMed ID: 31828108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Xp11 translocation renal cell carcinoma and clear cell renal cell carcinoma with TFE3 strong positive immunostaining: morphology, immunohistochemistry, and FISH analysis.
    Yang B; Duan H; Cao W; Guo Y; Liu Y; Sun L; Zhang J; Sun Y; Ma Y
    Mod Pathol; 2019 Oct; 32(10):1521-1535. PubMed ID: 31175325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.
    Rao Q; Williamson SR; Zhang S; Eble JN; Grignon DJ; Wang M; Zhou XJ; Huang W; Tan PH; Maclennan GT; Cheng L
    Am J Surg Pathol; 2013 Jun; 37(6):804-15. PubMed ID: 23598965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA sequencing of Xp11 translocation-associated cancers reveals novel gene fusions and distinctive clinicopathologic correlations.
    Wang XT; Xia QY; Ye SB; Wang X; Li R; Fang R; Shi SS; Zhang RS; Tan X; Chen JY; Sun K; Teng XD; Ma HH; Lu ZF; Zhou XJ; Rao Q
    Mod Pathol; 2018 Sep; 31(9):1346-1360. PubMed ID: 29713041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service.
    Green WM; Yonescu R; Morsberger L; Morris K; Netto GJ; Epstein JI; Illei PB; Allaf M; Ladanyi M; Griffin CA; Argani P
    Am J Surg Pathol; 2013 Aug; 37(8):1150-63. PubMed ID: 23715164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SFPQ/PSF-TFE3 renal cell carcinoma: a clinicopathologic study emphasizing extended morphology and reviewing the differences between SFPQ-TFE3 RCC and the corresponding mesenchymal neoplasm despite an identical gene fusion.
    Wang XT; Xia QY; Ni H; Ye SB; Li R; Wang X; Shi SS; Zhou XJ; Rao Q
    Hum Pathol; 2017 May; 63():190-200. PubMed ID: 28315422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological Findings on 28 Cases with XP11.2 Renal Cell Carcinoma.
    Kuthi L; Somorácz Á; Micsik T; Jenei A; Hajdu A; Sejben I; Imre D; Pósfai B; Kóczián K; Semjén D; Bajory Z; Kulka J; Iványi B
    Pathol Oncol Res; 2020 Oct; 26(4):2123-2133. PubMed ID: 31955345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RBM10-TFE3 renal cell carcinoma characterised by paracentric inversion with consistent closely split signals in break-apart fluorescence in-situ hybridisation: study of 10 cases and a literature review.
    Kato I; Furuya M; Baba M; Kameda Y; Yasuda M; Nishimoto K; Oyama M; Yamasaki T; Ogawa O; Niino H; Nakaigawa N; Yano Y; Sakamoto K; Urata Y; Mikami K; Yamasaki S; Tanaka R; Takagi T; Kondo T; Nagashima Y
    Histopathology; 2019 Aug; 75(2):254-265. PubMed ID: 30908700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular cytogenetic analysis for TFE3 rearrangement in Xp11.2 renal cell carcinoma and alveolar soft part sarcoma: validation and clinical experience with 75 cases.
    Hodge JC; Pearce KE; Wang X; Wiktor AE; Oliveira AM; Greipp PT
    Mod Pathol; 2014 Jan; 27(1):113-27. PubMed ID: 23828314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Xp11 neoplasm with melanocytic differentiation of the prostate harbouring the novel NONO-TFE3 gene fusion: report of a unique case expanding the gene fusion spectrum.
    Wang XT; Xia QY; Ni H; Wang ZY; Ye SB; Li R; Wang X; Lv JH; Shi SS; Ma HH; Lu ZF; Shen Q; Zhou XJ; Rao Q
    Histopathology; 2016 Sep; 69(3):450-8. PubMed ID: 26844676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinicopathological characteristics of fumarate hydratase-deficient renal cell carcinoma].
    Zhang W; Chu J; Zou YW; Jiang YX; Wei ZM; Zhong DC; Liu Y; Li YJ; Yu WJ
    Zhonghua Bing Li Xue Za Zhi; 2019 Feb; 48(2):120-126. PubMed ID: 30695864
    [No Abstract]   [Full Text] [Related]  

  • 19. RBM10-TFE3 Renal Cell Carcinoma: A Potential Diagnostic Pitfall Due to Cryptic Intrachromosomal Xp11.2 Inversion Resulting in False-negative TFE3 FISH.
    Argani P; Zhang L; Reuter VE; Tickoo SK; Antonescu CR
    Am J Surg Pathol; 2017 May; 41(5):655-662. PubMed ID: 28296677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RBM10-TFE3 fusions: A FISH-concealed anomaly in adult renal cell carcinomas displaying a variety of morphological and genomic features: Comprehensive study of six novel cases.
    Di Mauro I; Dadone-Montaudie B; Sibony M; Ambrosetti D; Molinie V; Decaussin-Petrucci M; Bland V; Arbaud C; Cenciu B; Arbib F; Just PA; Derman J; Rioux-Leclercq N; Pedeutour F;
    Genes Chromosomes Cancer; 2021 Nov; 60(11):772-784. PubMed ID: 34358382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.